文献速递临床试验与 GCP流行病学与生物统计

急性冠脉综合征与非急性冠脉综合征患者降阶为替格瑞洛单药治疗对比12个月双联抗血小板治疗:随机试验的系统综述与个体患者水平Meta分析

De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
PubMed 文献 · Lancet · 2024-08-31

该研究为系统综述与个体患者水平Meta分析,纳入6项随机试验,比较短期DAPT后降阶为替格瑞洛单药(90 mg每日两次)与持续12个月DAPT。在符合方案人群23256例中,MACCE非劣效(HR 0.91,95%CI 0.78-1.07;非劣效p=0.0039);在意向治疗人群24407例中,替格瑞洛单药降低BARC 3或5级出血(HR 0.43,95%CI 0.34-0.54;优效性p<0.0001)和全因死亡(HR 0.76,95%CI 0.59-0.98;优效性p=0.034)。

要点

  • 短期DAPT后降阶为替格瑞洛单药(90 mg每日两次)不增加缺血风险,且降低大出血风险。
  • 替格瑞洛单药组BARC 3或5级出血Kaplan-Meier估计0.9% vs DAPT组2.1%(HR 0.43)。
  • 全因死亡Kaplan-Meier估计0.9% vs 1.2%(HR 0.76),替格瑞洛单药可能带来生存获益。

核心结论

  • 与12个月DAPT相比,降阶为替格瑞洛单药不增加缺血风险并降低大出血风险,尤其在ACS患者中。
  • 替格瑞洛单药可能还与死亡获益相关,尤其在女性中,需进一步研究。

研究设计与样本

  • 系统综述与个体患者数据水平Meta分析,纳入6项随机试验,比较短期DAPT(2周至3个月)后替格瑞洛单药(90 mg每日两次)与12个月DAPT。
  • 检索Ovid MEDLINE、Embase及两个网站从建库至2024年5月20日,排除需长期口服抗凝药的患者。
  • 主要终点:MACCE在符合方案人群中检验非劣效性;BARC 3或5级出血和全因死亡在意向治疗人群中检验优效性。
  • 非劣效界值1.15(HR尺度),单侧α=0.025;优效性检验双侧α=0.05。
  • 符合方案人群23256例,意向治疗人群24407例;降阶中位时间78天(IQR 31-92),中位治疗时长334天(329-365)。

主要发现

  • 符合方案人群23256例中,MACCE替格瑞洛单药组297例(Kaplan-Meier估计2.8%)vs DAPT组332例(3.2%),HR 0.91(95%CI 0.78-1.07),非劣效p=0.0039,τ²<0.0001。
  • 意向治疗人群24407例中,BARC 3或5级出血替格瑞洛单药组Kaplan-Meier估计0.9% vs DAPT组2.1%,HR 0.43(95%CI 0.34-0.54),优效性p<0.0001,τ²=0.079。
  • 全因死亡替格瑞洛单药组Kaplan-Meier估计0.9% vs DAPT组1.2%,HR 0.76(95%CI 0.59-0.98),优效性p=0.034,τ²<0.0001。
  • 试验序贯分析显示总体和ACS人群中MACCE非劣效及出血优效证据强。
  • MACCE(交互p=0.041)和全因死亡(交互p=0.050)的治疗效应按性别异质,出血按临床表现为异质(交互p=0.022),提示ACS患者中替格瑞洛单药获益。

局限性

  • MACCE和全因死亡的治疗效应按性别存在异质性(交互p=0.041和p=0.050),提示女性中替格瑞洛单药可能获益。
  • 出血的治疗效应按临床表现存在异质性(交互p=0.022),提示ACS患者中替格瑞洛单药获益。
  • 替格瑞洛单药可能与死亡获益相关,尤其在女性中,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiplatelet therapy (DAPT) for 12 months is the standard of care after coronary stenting in patients with acute coronary syndrome (ACS). The aim of this individual patient-level meta-analysis was to summarise the evidence comparing DAPT de-escalation to ticagrelor monotherapy versus continuing DAPT for 12 months after coronary drug-eluting stent implantation. METHODS: A systematic review and individual patient data (IPD)-level meta-analysis of randomised trials with centrally adjudicated endpoints was performed to evaluate the comparative efficacy and safety of ticagrelor monotherapy (90 mg twice a day) after short-term DAPT (from 2 weeks to 3 months) versus 12-month DAPT in patients undergoing percutaneous coronary intervention with a coronary drug-eluting stent. Randomised trials comparing P2Y12 inhibitor monotherapy with DAPT after coronary revascularisation were searched in Ovid MEDLINE, Embase, and two websites (www.tctmd.com and www.escardio.org) from database inception up to May 20, 2024. Trials that included patients with an indication for long-term oral anticoagulants were excluded. The risk of bias was assessed using the revised Cochrane risk-of-bias tool. The principal investigators of the eligible trials provided IPD by means of an anonymised electronic dataset. The three ranked coprimary endpoints were major adverse cardiovascular or cerebrovascular events (MACCE; a composite of all-cause death, myocardial infarction, or stroke) tested for non-inferiority in the per-protocol population; and Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding and all-cause death tested for superiority in the intention-to-treat population. All outcomes are reported as Kaplan-Meier estimates. The non-inferiority was tested using a one-sided α of 0·025 with the prespecified non-inferiority margin of 1·15 (hazard ratio [HR] scale), followed by the ranked superiority testing at a two-sided α of 0·05. This study is registered with PROSPERO (CRD42024506083). FINDINGS: A total of 8361 unique citations were screened, of which 610 records were considered potentially eligible during the screening of titles and abstracts. Of these, six trials that randomly assigned patients to ticagrelor monotherapy or DAPT were identified. De-escalation took place a median of 78 days (IQR 31-92) after intervention, with a median duration of treatment of 334 days (329-365). Among 23 256 patients in the per-protocol population, MACCE occurred in 297 (Kaplan-Meier estimate 2·8%) with ticagrelor monotherapy and 332 (Kaplan-Meier estimate 3·2%) with DAPT (HR 0·91 [95% CI 0·78-1·07]; p=0·0039 for non-inferiority; τ2<0·0001). Among 24 407 patients in the intention-to-treat population, the risks of BARC 3 or 5 bleeding (Kaplan-Meier estimate 0·9% vs 2·1%; HR 0·43 [95% CI 0·34-0·54]; p<0·0001 for superiority; τ2=0·079) and all-cause death (Kaplan-Meier estimate 0·9% vs 1·2%; 0·76 [0·59-0·98]; p=0·034 for superiority; τ2<0·0001) were lower with ticagrelor monotherapy. Trial sequential analysis showed strong evidence of non-inferiority for MACCE and superiority for bleeding among the overall and ACS populations (the z-curve crossed the monitoring boundaries or the required information size without crossing the futility boundaries or approaching the null). The treatment effects were heterogeneous by sex for MACCE (p interaction=0·041) and all-cause death (p interaction=0·050), indicating a possible benefit in women with ticagrelor monotherapy, and by clinical presentation for bleeding (p interaction=0·022), indicating a benefit in ACS with ticagrelor monotherapy. INTERPRETATION: Our study found robust evidence that, compared with 12 months of DAPT, de-escalation to ticagrelor monotherapy does not increase ischaemic risk and reduces the risk of major bleeding, especially in patients with ACS. Ticagrelor monotherapy might also be associated with a mortality benefit, particularly among women, which warrants further investigation. FUNDING: Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Valgimigli M, Hong SJ, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024. PMID: 39226909. doi:10.1016/S0140-6736(24)01616-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。